Can-Fite BioPharma Ltd.
CANF- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001536196
No open-market purchases or sales by Can-Fite BioPharma Ltd. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $149.1K in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −6 vs. previous quarter
- 8
- 13F valueReported value at the end of Q2 2026
- $149.1K
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding CANF, Q2 2026
No superinvestor reported holding CANF at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Can-Fite BioPharma Ltd. insiders from Form 4, newest first.
No open-market purchases or sales by Can-Fite BioPharma Ltd. insiders are on file.
Top 10 13F holders, Q2 2026
The largest institutional positions in Can-Fite BioPharma Ltd. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Citadel Advisors LLC | 32,533 | $96.6K | 0.00% | −1,617−4.7% | Reduced |
| Rhumbline Advisers | 17,433 | $51.8K | 0.00% | −3,475−16.6% | Reduced |
| Fifth Third Bancorp | 150 | $446 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 59 | $175 | 0.00% | −66−52.8% | Reduced |
| Activest Wealth Management | 10 | $30 | 0.00% | 00.0% | Unchanged |
| TD Waterhouse Canada Inc. | 1 | $4 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 1 | $3 | 0.00% | 00.0% | Unchanged |
| Avion Wealth | 5 | $0 | 0.00% | 00.0% | Unchanged |